Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

AMF Regulated Information

AMF Documents
AMF Press Releases

AMF Documents
AMF Press Releases

AMF Documents

Search Filings

Found 192 Results

Page 6 of 20« First «...4 567 8...20...»Last »

December 15, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2020

November 11, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2020

October 8, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2020

September 15, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2020

August 12, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2020

July 31, 2020

Half year financial report 2020

July 31, 2020

DBV Technologies Reports First Half 2020 Financial Results

July 31, 2020

Half year financial report 2020

July 15, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2020

June 11, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020

Page 6 of 20« First «...4 567 8...20...»Last »

Latest AMF Press Releases

July 6, 2026

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

June 3, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026

June 3, 2026

DBV Technologies Announces the Results of its 2026 Combined General Meeting

View All Press Releases

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Your California Privacy Rights

Scroll to Top